These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 23863458)
21. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Chantada GL; Dunkel IJ; Antoneli CB; de Dávila MT; Arias V; Beaverson K; Fandiño AC; Chojniak M; Abramson DH Pediatr Blood Cancer; 2007 Sep; 49(3):256-60. PubMed ID: 17029248 [TBL] [Abstract][Full Text] [Related]
22. Clinical manifestations and treatment of retinoblastoma in Korea. Chung SE; Sa HS; Koo HH; Yoo KH; Sung KW; Ham DI Br J Ophthalmol; 2008 Sep; 92(9):1180-4. PubMed ID: 18650212 [TBL] [Abstract][Full Text] [Related]
23. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977 [TBL] [Abstract][Full Text] [Related]
24. Chemoreduction in the management of retinoblastoma. Shields JA; Shields CL; Meadows AT Am J Ophthalmol; 2005 Sep; 140(3):505-6. PubMed ID: 16139001 [No Abstract] [Full Text] [Related]
25. [Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma]. Balwierz W; Pietrys D; Romanowska-Dixon B; Kobylarz J; Pawińska-Wasikowska K; Moryl-Bujakowska A Przegl Lek; 2010; 67(6):404-8. PubMed ID: 21344770 [TBL] [Abstract][Full Text] [Related]
26. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Narang S; Mashayekhi A; Rudich D; Shields CL Clin Exp Ophthalmol; 2012; 40(7):736-42. PubMed ID: 22300311 [TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Berry JL; Jubran R; Kim JW; Wong K; Bababeygy SR; Almarzouki H; Lee TC; Murphree AL Pediatr Blood Cancer; 2013 Apr; 60(4):688-93. PubMed ID: 22997170 [TBL] [Abstract][Full Text] [Related]
28. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Gündüz K; Shields CL; Shields JA; Meadows AT; Gross N; Cater J; Needle M Arch Ophthalmol; 1998 Dec; 116(12):1613-7. PubMed ID: 9869790 [TBL] [Abstract][Full Text] [Related]
29. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Shields CL; Mashayekhi A; Sun H; Uysal Y; Friere J; Komarnicky L; Shields JA Ophthalmology; 2006 Nov; 113(11):2087-92. PubMed ID: 16949158 [TBL] [Abstract][Full Text] [Related]
30. [Results of combined chemotherapy and local ophtalmic therapy of children with intraocular retinoblastoma]. Balwierz W; Kobylarz J; Starzycka M; Dluzniewska A Med Wieku Rozwoj; 2001; 5(3 Suppl 1):15-23. PubMed ID: 12004148 [TBL] [Abstract][Full Text] [Related]
31. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Demirci H; Eagle RC; Shields CL; Shields JA Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690 [TBL] [Abstract][Full Text] [Related]
32. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Lambert MP; Shields C; Meadows AT Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120 [TBL] [Abstract][Full Text] [Related]
33. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319 [TBL] [Abstract][Full Text] [Related]
34. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide. Varan A; Kiratli H; Aydın B; Tarlan B; Poyraz CB; Akyüz C; Büyükpamukçu M Pediatr Hematol Oncol; 2012 Sep; 29(6):529-37. PubMed ID: 22759219 [TBL] [Abstract][Full Text] [Related]
35. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Wilson MW; Haik BG; Liu T; Merchant TE; Rodriguez-Galindo C Am J Ophthalmol; 2005 Sep; 140(3):397-406. PubMed ID: 16138999 [TBL] [Abstract][Full Text] [Related]
36. The success of primary chemotherapy for group D heritable retinoblastoma. Cohen VM; Kingston J; Hungerford JL Br J Ophthalmol; 2009 Jul; 93(7):887-90. PubMed ID: 18703556 [TBL] [Abstract][Full Text] [Related]
37. Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. Chawla B; Hasan F; Seth R; Pathy S; Pattebahadur R; Sharma S; Upadhyaya A; Azad R Ophthalmology; 2016 Sep; 123(9):1933-9. PubMed ID: 27449712 [TBL] [Abstract][Full Text] [Related]
38. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213 [TBL] [Abstract][Full Text] [Related]
39. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Murphree AL; Villablanca JG; Deegan WF; Sato JK; Malogolowkin M; Fisher A; Parker R; Reed E; Gomer CJ Arch Ophthalmol; 1996 Nov; 114(11):1348-56. PubMed ID: 8906025 [TBL] [Abstract][Full Text] [Related]